Avibactam pharmacokinetic/pharmacodynamic targets

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 6, 2018, Pages

  Nichols, Wright W ^a   Newell, Paul ^a,d   Critchley, Ian A ^b,e   Riccobene, Todd ^c   Das, Shampa ^a,f  

^a ASTRAZENECA   (United Kingdom)

^b ALLERGAN INC   (United States)

^c ALLERGAN PLC   (United States)

^d F2G LTD   (United Kingdom)

^e Drug Product Development   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Avibactam; BL BLI; Diazabicyclooctane; PK PD

Indexed keywords

AVIBACTAM; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFTAROLINE; CEFTAZIDIME; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; CEPHALOSPORIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG SYNTHESIS; ENTEROBACTERIACEAE; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRECLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS;

EID: 85047499934     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02446-17     Document Type: Review

References (59)

1. Mager DE, Woo S, Jusko WJ. 2009. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16–24. https://doi.org/10.2133/dmpk.24.16.
2. Bueters T, Gibson C, Visser SA. 2015. Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Med Chem 7:2351–2369. https://doi.org/10.4155/fmc.15.143.
3. Felmlee MA, Morris ME, Mager DE. 2012. Mechanism-based pharmacodynamic modeling. Methods Mol Biol 929:583–600. https://doi.org/10.1007/978-1-62703-050-2_21.
4. Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, Jadhav PR, Krudys K, Lesko LJ, Li F, Liu J, Madabushi R, Marathe A, Mehrotra N, Tornoe C, Wang Y, Zhu H. 2011. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 50:627– 635. https://doi.org/10.2165/11593210-000000000-00000.
5. Sundqvist M, Lundahl A, Nagard MB, Bredberg U, Gennemark P. 2015. Quantifying and communicating uncertainty in preclinical human dose-prediction. CPT Pharmacometrics Syst Pharmacol 4:243–254. https://doi .org/10.1002/psp4.32.
6. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86. https://doi.org/10.1086/510079.
7. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D -lactamases. J Biol Chem 288:27960–27971. https://doi.org/10.1074/jbc.M113.485979.
8. Sader H, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. 2015. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59:3656–3659. https://doi.org/10.1128/AAC.05024-14.
9. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. 2016. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749. https://doi.org/10.1128/AAC .00220-16.
10. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. 2016. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60:3163–3169. https://doi.org/10.1128/AAC.03042-15.
11. Allergan. 2018. AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use. Prescribing information. http://www.allergan.com/assets/pdf/avycaz_pi. Accessed 7 February 2018.
12. Pfizer. 2016. ZAVICEFTA. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf. Accessed 7 February 2018.
13. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390 –394. https://doi.org/10.1128/AAC.00756-10.
14. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo--lactamase producers. Antimicrob Agents Chemother 57:3299–3306. https://doi.org/10.1128/AAC.01989-12.
15. Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. 2015. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59:4239 – 4248. https://doi.org/10.1128/AAC.00206-15.
16. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. 2012. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more -lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother 56:4779 – 4785. https://doi.org/10.1128/AAC.00817-12.
17. Pfizer 2017. NCT02655419. Determine the PK and safety and tolerability of ATM-AVI for the treatment of cIAIs in hospitalized adults (REJUVENATE). https://clinicaltrials.gov/ct2/show/NCT02655419. Accessed 7 February 2018.
18. Forest Laboratories. 2017. NCT01281462. Comparative study of co-administered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. https://clinicaltrials.gov/ct2/show/NCT01281462. Accessed 7 February 2018.
19. European Medicines Agency. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. Document EMA/CHMP/594085/2015. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/ 07/WC500210982.pdf. Accessed 7 February 2018.
20. Nielsen EI, Friberg LE. 2013. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053–1090. https://doi.org/10.1124/pr.111.005769.
21. Rex JH, Goldberger M, Eisenstein BI, Harney C. 2014. The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci 1323: 11–21. https://doi.org/10.1111/nyas.12441.
22. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, MacGowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G. 2012. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18:E37–E45. https://doi.org/10.1111/j.1469-0691.2011.03752.x.
23. Muller AE, Punt N, Mouton JW. 2013. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68: 900–906. https://doi.org/10.1093/jac/dks468.
24. Kuti JL, Nicolau DP. 2005. Making the most of surveillance studies: summary of the OPTAMA program. Diagn Microbiol Infect Dis 53: 281–287. https://doi.org/10.1016/j.diagmicrobio.2005.10.004.
25. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301–1309. https://doi .org/10.1093/cid/cit017.
26. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289 –300. https://doi.org/10.1038/nrmicro862.
27. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55:601– 607. https://doi.org/10.1093/jac/dki079.
28. Dudley MN. 1995. Combination -lactam and -lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Am J Health Syst Pharm 52:S23–S28.
29. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19: 261–268. https://doi.org/10.1016/S0924-8579(02)00022-5.
30. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of -lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479–501. https://doi.org/10.1016/S0891-5520(03)00065-5.
31. Craig WA. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p 1–19. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare, New York, NY.
32. MacVane SH, Kuti JL, Nicolau DP. 2014. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 58:1359–1364. https://doi.org/10.1128/AAC.01463-13.
33. DeRyke CA, Kuti JL, Nicolau DP. 2007. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337–344. https://doi.org/10.1016/j.diagmicrobio.2007.01.004.
34. Frei CR, Wiederhold NP, Burgess DS. 2008. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61:621–628. https://doi.org/10.1093/jac/dkm536.
35. EUCAST. 2010. Ceftazidime. Rationale for the EUCAST clinical breakpoints, version 1.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ceftazidime_Rationale_Document _1.0_2010Nov.pdf. Accessed 7 February 2018.
36. Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW. 2014. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 26: 333–338. https://doi.org/10.1179/1973947813Y.0000000145.
37. Sader H, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58:1684–1692. https://doi.org/10.1128/AAC.02429-13.
38. Levasseur P, Girard A-M, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 56:1606–1608. https://doi.org/10.1128/AAC.06064-11.
39. Walkty A, DeCorby M, Lagacé-Wiens P, Karlowsky J, Hoban D, Zhanel G. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 55: 2992–2994. https://doi.org/10.1128/AAC.01696-10.
40. Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q. 2014. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 58:1774–1778. https://doi.org/10.1128/AAC.02123-13.
41. Reference deleted.
42. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother 58:833– 838. https://doi.org/10.1128/AAC.01896-13.
43. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against -lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58:3366–3372. https://doi.org/10.1128/AAC.00080-14.
44. Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. 2016. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother 60:368 –375. https://doi.org/10.1128/AAC.01269-15.
45. European Medicines Agency. 2016. Zavicefta. European public assessment report. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004027/WC500210236.pdf. Accessed 7 February 2018.
46. Cerexa, Inc. 2014. Briefing package, NDA 206494: ceftazidime-avibactam. Cerexa, Inc., Alameda, CA. https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2014/ December/12314%20FDA%20briefing%20docs.pdf.
47. Nicolau DP. 2015. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs 24:1261–1273. https://doi.org/10.1517/13543784.2015.1062873.
48. Mawal Y, Critchley IA, Riccobene TA, Talley AK. 2015. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol 8:691–707. https://doi.org/10.1586/17512433.2015.1090874.
49. Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O’Donnell JP, Bradford PA, Eakin AE. 2015. Pharmacokinetics/pharmacodynamics of a -lactam and -lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 70:2618 –2626. https://doi.org/10.1093/jac/dkv132.
50. Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL. 2012. Pharmacodynamics of -lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of -lactamases. Antimicrob Agents Chemother 56:258 –270. https://doi.org/10.1128/AAC.05005-11.
51. MacGowan A, Tomaselli S, Noel A, Bowker K. 2017. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against -lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. J Antimicrob Chemother 72:762–769. https://doi.org/10.1093/jac/dkw480.
52. Das S, Riccobene T, Carrothers T, Wright J, Macpherson M, Lovern M, Hing J, Xiong Y, Taylor A, Comisar C. 2017. Pharmacokinetic/ pharmacodynamic validation of the ceftazidime-avibactam dose in patients with nosocomial pneumonia, including ventilator-associated pneumonia, poster P1185. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22 to 25 April 2017.
53. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. 2016. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380–1389. https://doi.org/10.1093/cid/ciw133.
54. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673. https://doi.org/10.1016/S1473-3099(16)30004-4.
55. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. 2016. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754–762. https://doi.org/10.1093/cid/ciw378.
56. Qin X, Tran BG, Kim M, Wang L, Nguyen D, Chen Q, Song J, Laud PJ, Stone GG, Chow JW. 2017. A randomized, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents 49:579–588. https://doi.org/10.1016/j.ijantimicag.2017.01.010.
57. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW. 2018. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18:285–295. https://doi.org/10.1016/S1473-3099(17)30747-8.
58. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
59. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.